PubMed

Physician-Patient Communication about Novel Drugs and High-Risk Medical Devices.

PMID: 39707817 · 2024-12-21

S, a, n, k, e, t, , S, , D, h, r, u, v, a, ;, , A, a, r, o, n, , S, , K, e, s, s, e, l, h, e, i, m, ;, , S, t, e, v, e, n, , W, o, l, o, s, h, i, n, ;, , R, o, b, i, n, , Z, , J, i, ;, , Z, h, i, g, a, n, g, , L, u, ;, , J, o, n, a, t, h, a, n, , J, , D, a, r, r, o, w, ;, , R, i, t, a, , F, , R, e, d, b, e, r, g

JournalMedical decision making : an international journal of the Society for Medical Decision Making

Year2024-12-21

PMID39707817

Abstract

After a new drug or medical device is approved by the US Food and Drug Administration (FDA), physician-patient communication about benefits and risks is critical, including whether the product was approved through an expedited pathway based on limited evidence. In addition, physician reporting of drug- and device-related adverse events in real-world use is necessary to have a complete safety profile. We studied physician-reported communication and safety-reporting practices related to drugs and

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.